The Weave Platform is an AI-native solution built to support regulatory workflows across the therapeutic lifecycle.
Weave Bio, a pioneer in AI-native regulatory automation management solutions, announced its $20 million Series A funding, bringing the company’s total capital raised to $36 million. The round was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
The Weave Platform is an AI-native solution built to support regulatory workflows across the entire lifecycle of a therapeutic. Designed for pharmaceutical companies, biotech firms, CROs, and regulatory consultants, the platform helps teams prepare and manage complex dossiers more efficiently by combining AI-powered data organization, authoring, review, publishing, and streamlined responses to health authority questions. With Weave’s human-powered, AI-driven platform, regulatory teams gain the speed, consistency, and confidence needed to enhance quality and reduce time, effort, and cost.
Also Read: PubHive AI Dashboard Boosts Governance & Cost Efficiency
“Regulatory workflows are the backbone of a therapeutic candidate’s success, requiring scientific precision, strategic expertise, and meticulous execution. Historically, these processes have been entirely manual, and therefore time-consuming and costly,” said Brandon Rice, CEO and co-founder of Weave. “With the Weave Platform, a new paradigm is emerging wherein every stage of the workflow is intelligently infused with AI, dramatically accelerating the process and empowering teams to focus on those areas that uniquely benefit from human judgement and expertise. This new funding will enable us to expand the reach of our platform and extend its capabilities to provide our customers with even greater speed and control.”
With this capital, Weave will accelerate product development and expand its commercial team to further solidify its market leadership.
The financing will enable Weave to:
- Complete its coverage of the entire regulatory lifecycle of therapeutics, inclusive of market applications (NDA/BLA), responses to health authority questions (HAQ/RTQ), and post-market updates and submissions.
- Expand into global markets beyond the U.S. FDA, including Europe, Japan, and Latin America.
- Build advanced AI capabilities that will provide insights into therapeutic portfolios and empower strategic decision-making across the drug development process.
“Weave is redefining regulatory workflows with the first AI-native platform built for drug development. It’s modern, intuitive, and built to scale exactly the type of innovation we look to back at USVP,” said Matt Garratt, General Partner at USVP. “We’re excited to support the team as they help bring life-changing therapies to patients faster.”
Source: Businesswire